Selonsertib, originally developed for liver failure, inhibits apoptosis signal-regulating kinase 1 (ASK1), thereby reducing inflammation, apoptosis, and fibrosis, making it a potential PH treatment [100]. This evidence concerns the gene MAP3K5 and liver failure.